Anti-CD40 was combined with anti-CSF-1R to create a pro-inflammatory environment eliciting T-cell responses before depletion of TAMs [75] or with chemotherapies such as imatinib (tyrosine kinase inhibitor) with strong tumor regression in a gastrointestinal tumor mouse model [76]. This evidence concerns the gene CD40 and neoplasm.